Thank you for the question regarding CMS69v12: Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan. The value set “Medications for Above Normal BMI” (OID: 2.16.840.1.113883.3.526.3.1561) contains the pharmacological interventions for overweight or obesity that are included in the measure. You can reference the applicable codes contained in this value set on the Value Set Authority Center (VSAC) at https://vsac.nlm.nih.gov/ . Click on the “Search Value Sets” tab and enter the value set ID to review codes included in the value set. Medications that are prescribed off-label or for diagnoses other than overweight or obesity are not included as an intervention for overweight or obesity.

In terms of follow-up strategies outlined in CMS69v12, numerous patients receive prescriptions for diabetes medications, some of which, like Semaglutide (Ozempic), Dulaglutide (Trulicity), and Tirzepatide (Mounjaro) serve dual purposes by aiding weight loss. Do these medications meet the requirements for follow-up plans involving pharmacological interventions? Additionally, what other medications should be considered for inclusion in pharmacological interventions?